Study Summary
This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.
Want to learn more about this trial?
Request More InfoInterventions
IL-15-armored CAR-T cellsBIOLOGICAL
BCMA-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells; CD19/BCMA dual-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells; GPRC5D-targeted: 1.0/2.0/3.0 × 10\^6 CAR-T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Hospital of Jilin University | Changchun | Jilin | China |